ArticleScientific reports2026
Functionalization of magnetic TMU-17-NH
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel magnetic nanocatalyst, Cu@M-TMU-17-NH₂-Gly-Met, was successfully prepared through a multi-step post-synthetic modification strategy. Initially, the TMU-17-NH₂ framework was functionalized with glyoxal, followed by immobilization of metformin to introduce nitrogen-rich coordination sites for copper incorporation. The composition and structural integrity of the resulting nanocomposite were confirmed by FT-IR, TGA, XRD, FE-SEM, EDX, BET, ICP-MS, and VSM analyses. The catalytic performance of the prepared nanocomposite was evaluated in the synthesis of dihydropyrimidinone derivatives via the Biginelli reaction, as well as in the synthesis of 2-amino-4H-pyran derivatives through a multicomponent reaction strategy. The results demonstrated that the catalyst efficiently promoted both reactions under mild conditions, affording high yields (73-92% and 79-98%, respectively) within short reaction times. The catalyst exhibited excellent reusability and stability over several cycles with a gradual and acceptable decrease in yield (from 89% to 74% for the Biginelli reaction, and from 96% to 84% for the pyran synthesis) over seven consecutive cycles for model reaction The combination of high efficiency, ease of separation, and environmental compatibility highlights the potential of this nanocatalyst for practical applications in organic synthesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.